Meningioma Clinical Trial
Official title:
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
The purpose of this study is to find out what effects, good and/or bad, sunitinib has on
patients and their tumors. At this time, no drugs are routinely used to treat meningioma,
hemangioblastoma or hemangiopericytoma. Only surgery and radiation therapy are known to be
useful.
Sunitinib is a drug approved for advanced kidney cancer. Sunitinib is also being studied for
other tumors. It may be useful in the treatment of brain tumors because it can prevent
formation of new blood vessels that allow tumor cells to survive and grow.
This is a phase II study of Sunitinib in patients with recurrent or inoperable meningiomas. An exploratory study will be performed for patients with recurrent hemangiopericytoma or hemangioblastoma. There will be approximately 50 patients enrolled on this study (40 meningiomas and 10 hemangiopericytomas/hemangioblastomas). The treatment plan is to use daily SU11248 at a dose of 50 mg, using the established schedule of 4 weeks of treatment followed by two weeks of rest period, forming a six-week treatment cycle. A medical professional will see each patient at least every six weeks while on the medication for toxicity assessment and physical examination. Extent of disease evaluations will occur at baseline, two weeks, twelve weeks, 24 weeks, and every twelve weeks thereafter. These evaluations will include MRI of the brain (or CT head if a patient cannot undergo MRI) and MR perfusion. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04081701 -
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
|
Phase 4 | |
Recruiting |
NCT03631953 -
Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas
|
Phase 1 | |
Completed |
NCT03273712 -
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
|
Phase 2 | |
Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
Withdrawn |
NCT00985036 -
Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients
|
N/A | |
Completed |
NCT01347307 -
Stereotactic Body Radiotherapy for Spine Tumors
|
N/A | |
Completed |
NCT01811524 -
The Etiology and Progression of Brain Tumors
|
N/A | |
Completed |
NCT03648034 -
Effects of Scalp Nerve Block With Ropivacaine on Postoperative Recovery Quality
|
N/A | |
Recruiting |
NCT06036706 -
Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:
|
N/A | |
Recruiting |
NCT06014905 -
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
|
Phase 1 | |
Not yet recruiting |
NCT04386642 -
Tranexamic Acid Reduce Blood Loss in Meningioma Resection
|
Phase 4 | |
Active, not recruiting |
NCT04595786 -
The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection
|
N/A | |
Completed |
NCT04305470 -
Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma
|
Phase 3 | |
Completed |
NCT01967823 -
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
|
Phase 2 | |
Not yet recruiting |
NCT02978677 -
Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas
|
N/A | |
Active, not recruiting |
NCT02933736 -
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
|
Early Phase 1 | |
Completed |
NCT02267928 -
Information Presentation Formats
|
N/A | |
Active, not recruiting |
NCT03071874 -
Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
|
Phase 2 | |
Recruiting |
NCT05416567 -
Embolization for Meningioma
|
N/A | |
Not yet recruiting |
NCT06126588 -
Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial
|
Phase 2 |